No recent analyst price targets found for ALMR.
Latest News for ALMR
Alamar Biosciences Burns Cash In Runup To IPO
Alamar Biosciences, Inc. is pursuing a likely $100 million IPO to fund scaling of its protein biomarker diagnostics business. ALMR's revenue surged 195% to $74.2M in 2025, with gross margin expanding to 56.2%, though cash burn and operating losses remain significant. The company's growth strategy centers on expanding its installed base, recurring consumables revenue, and assay menu into oncology and cardiometabolic…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ALMR.
Senate Trading
No Senate trades found for ALMR.
U.S. House Trading
No House trades found for ALMR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.